Target intelligence / Profile preview

MicroRNA 203a (miR-203a)

Target
miR-203a
Molecular classification
MicroRNA, Non-coding RNA, Regulatory RNA, Other
01

Overview

MicroRNA 203a (miR-203a) is a small, non-coding RNA of approximately 22 nucleotides, belonging to the microRNA class, with a locus at chromosome 14q32.33[5]. It exerts its function primarily through the post-transcriptional regulation of gene expression by binding to target mRNAs and repressing their translation or promoting degradation[5]. miR-203a acts as a tumor suppressor in several malignancies, including breast cancer, by inhibiting cell cycle progression, proliferation, migration, and by promoting apoptosis, frequently through interactions with genes like PIK3CA, Wnt2b, BMI1, WT1, and XIAP[1][3]. Its expression and methylation status have diagnostic and prognostic utility in various cancers and it has been investigated as a molecular biomarker[2][3][4][5]. There are no clinically approved drugs that directly target miR-203a, but it is being explored as an intervention point in experimental and preclinical tumor gene therapy research[3][5].

Other names
hsa-mir-203MIR203MIRN203hsa-mir-203amiR-203miRNA203mir-203amicroRNA 203MIR203A
02

Mechanism of action

Regulation by inhibition of translation or degradation of specific mRNA targets involved in oncogenic signaling (e.g., targeting PIK3CA, Wnt2b, BMI1, WT1, XIAP, BIRC5, LASP1)[1][3].

03

Biological functions

Post-transcriptional gene regulationCell cycle regulationRegulation of cell proliferationApoptosisCell migrationEpithelial-mesenchymal transition (EMT)
04

Disease associations

Cancer (including breast, bladder, ovarian, colon, lung, and chronic myeloid leukemia)PsoriasisTherapeutic resistance (chemo-resistance)Biomarker (diagnostic and prognostic in cancer)
05

Safety considerations

Potential off-target effects with therapeutic miRNA modulation (inferred from class)Unknown long-term risks of miRNA-based therapeutics (inferred; not specifically described in search results)
06

Interacting drugs

None reported as direct pharmacological agents; modulation studied in functional genomics and as a target for gene therapy/experimental inhibitors[3][5].
07

Biomarkers

Expression levels of miR-203a as a diagnostic/prognostic biomarker in breast cancer and chronic myeloid leukemia[2][3][4]Methylation status of the MIR203A locus as a biomarker in leukemia[3]

Beyond the preview

Go deeper on MicroRNA 203a (miR-203a).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 203a (miR-203a).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call